More on INSU
Data
Financials
News
Click line-items for a historical chart and %
| Cash flows from operating activities: | |
| Net income | 11.03M |
| Loss from discontinued operations | |
| Income from continuing operations | |
| Adjustments to reconcile to net cash provided by operating activities: | |
| Depreciation and amortization | 34.41M |
| (Gain) loss on sale of fixed assets | -1.96M |
| Equity-based compensation expense | 7.69M |
| Deferred income taxes | |
| Equity in earnings of affiliated companies | |
| Gain on foreign currency | |
| Changes in operating assets and liabilities (net of CRTS acquisition): | |
| Restricted cash | 1.7M |
| Return on equity method investments | |
| Receivables net, retainage and costs and estimated earnings in excess of billings | 26.4M |
| Inventories | -510K |
| Prepaid expenses and other assets | -3.09M |
| Accounts payable and accrued expenses | -41.7M |
| Other | 440K |
| Net cash provided by operating activities of continuing operations | |
| Net cash used in operating activities of discontinued operations | |
| Net cash provided by operating activities | 36.7M |
| Cash flows from investing activities: | |
| Capital expenditures | -31.49M |
| Proceeds from sale of fixed assets | 3.08M |
| Patent expenditures | -1.03M |
| Purchase of Singapore licensee | |
| Purchase of CRTS, net of cash acquired | -84.74M |
| Net cash used in investing activities | -120.23M |
| Cash flows from financing activities: | |
| Proceeds from issuance of common stock, including tax benefit of stock option exercises | |
| Proceeds from notes payable | 0 |
| Principal payments on notes payable | 0 |
| Investments from noncontrolling interests | |
| Distributions/dividends to noncontrolling interests | |
| Proceeds from line of credit | 42M |
| Debt amendment costs | |
| Principal payments on long-term debt | -13.13M |
| Net cash provided by (used in) financing activities | -15.46M |
| Effect of exchange rate changes on cash | 561K |
| Net decrease in cash and cash equivalents for the period | -98.43M |
| Cash and cash equivalents, beginning of period | 209.25M |
| Cash and cash equivalents, end of period | 113.26M |
